Unlike semaglutide which activates only GLP-1 receptors, or tirzepatide which targets GLP-1 and GIP, retatrutide simultaneously activates three hormone receptors
doi: 10.1111/dom.13340 44 WeinstockRSGuerciBUmpierrezGNauckMASkrivanekZMilicevicZ
At dLife, we've built our reputation on measurable outcomes, accountability, and confidence in our science-backed metabolic health approach
Do not self-administer retatrutide based on this chart
Christopher McGowan, a North Carolina physician who is triple board certified in internal medicine, gastroenterology and obesity medicine, calls microdosing programs murky and a complete Wild West. Dr
Some individuals view lower doses as a way to support short- or medium-term metabolic goals rather than committing to higher doses long term